AMBULATORY INFUSION CENTER MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Advancements in Specialized Biologics and Targeted Therapies

Over the last decade, there have been unprecedented advancements in drug development, resulting in a variety of new biologics, immunotherapies, and targeted treatment options. Unlike conventional chemotherapy which aims to destroy fast-dividing cells, these new generation therapies are highly specialized and focus on specific molecular targets associated with certain types of cancers and chronic diseases. While effective, many such biologics including monoclonal antibodies, stem cell therapies, and gene therapies can only be administered intravenously. Therefore, to benefit from these complex and cutting-edge IV-based therapies, patients routinely require long-term or lifetime infusion access in an ambulatory setting. This allows for the convenient administration of treatments at flexible timings over extended periods without disrupting daily activities or work schedule. The approvals of a growing number of targeted biologics coupled with oncology research exploring new infusion-based combinations is fueling the need for expanded outpatient infusion facilities across the globe. This has become a major driver responsible for the significant rise in demand for ambulatory infusion services worldwide.